Login / Signup

The Impact of Omitting 5-FU Bolus From mFOLFOX6 Chemotherapy Regimen on Hematological Adverse Events Among Patients With Metastatic Colorectal Cancer.

Nutthada AreepiumBannawich Sapapsap
Published in: World journal of oncology (2023)
mCRC patients who were treated with bolus 5-FU had lower ANC. The 5-FU bolus omission from the mFOLFOX6 regimen may be required in patients with a high risk of neutropenia.
Keyphrases
  • metastatic colorectal cancer
  • chemotherapy induced
  • randomized controlled trial
  • newly diagnosed
  • open label